CSI Market
Sign In | Register

Bionexus Gene Lab (BGLC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BGLC Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Bionexus Gene Lab's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-0.83
Depreciation & amortization0.06
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset0.00
Provision For Loan Losses Expensed0.39
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.01
Finance Lease Right Of Use Asset Amortization-
Dividend Income-
Fair Value Gain On Other Investments-
Property Plant And Equipment Disposals-
Operating Profit Loss Before Working Capital Changes-
Increasedecreaseindeferred Cost Of Revenue-
Operating Lease Right Of Use Asset Amortization Expense0.02
Property Plant And Equipment Additions-
Allowance For Stock Write Offs-
Operating Loss Profit Before Working Capital Changes-
Bad Debts Written Off-
Gain Loss On Sale Of Other Investments Equity Securities-
Gain Loss On Termination Of Lease-
Impairment Of Investments-
Property Plant And Equipment Written Off-
Stock Written Off-
Recoveries For Expected Credit Losses-0.03
Investment Income Dividend-
Equity Securities Fv Ni Realized Gain Loss-
Increase Decrease In Other Assets-0.25
Increase Decrease In Income Taxes Liabilities Receivable0.00
Income taxes0.00
Equity Method Investment, Realized Gain (Loss) on Disposal0.00
Increase (Decrease) in Accounts and Other Receivables0.00
Increase (Decrease) in Other Accounts Payable0.21
Accrued Expense0.00
Increase (Decrease) in Customer Advances0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.40
Discontinued operations0.00
Net Cash flow from Operating Activities-0.57
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Property Plant And Equipment Gross Period Increase Decrease-
Investment Income Interest And Dividend-
Net Cash From Acquisition Of Business Under Common Control-
Dividend Income Other-
Dividend Income Others-
Interest Income Expense Net-
Proceeds From Settlement Of Supplier Contract Dispute-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale of Other Investments0.44
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.04
Discontinued operations0.00
Net Cash Flow from Investing Activities0.40
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.08
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Advances To Affiliate-
Common Stock Shares Subscriptions-
Advance Repayments To Directors-
Shares Cancellation-
Repayment Of Finance Lease-
Shares Subscriptions-
Fixed Deposits Placed With Financial Institutions1.06
Repayment From Directors-
Cash Periods Increase Decrease-
Net Change In Cash And Cash Equivalents-
Proceed From Interst-
Finance Lease Principal Payments-
Payments For Shares Subscriptions-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.07
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.57
Total Cash Flow-0.09
4 historic quarters locked

Sign in to unlock the full Bionexus Gene Lab cash flow history.

Sign In Create Free Account

About Bionexus Gene Lab Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 14, 2026
  • Source: bglc_10q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001477932-26-005093

Figures are derived from filed reports and may be restated. Historical data is subject to revision.